
|Videos|July 15, 2021
An Overview of Aducanumab for the Treatment of Alzheimer Disease
Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.
Advertisement
In a recent interview with Pharmacy Times, Pamela Spicer, senior analyst with Datamonitor Healthcare at Informa Pharma Intelligence, reviewed the approval of aducanumab and what pharmacists should know about its use in patients with Alzheimer disease. Spicer said aducanumab is a once-monthly infusion with a 6-month titration schedule. It has several notable adverse effects, including amyloid-related imaging abnormalities which should be monitored closely.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Research Suggests Caffeinated Coffee or Tea Could Reduce Dementia Risk
2
FDA Declines to Review Moderna’s mRNA-1010 Flu Vaccine Application, Citing Comparator Concerns
3
Pembrolizumab Combination FDA-Approved for Ovarian Cancer
4
Q&A: Cutting Through Cost and Misinformation in GLP-1 Therapy
5








































